Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Farmers Insurance
Johnson and Johnson
Teva
Medtronic
Covington
Boehringer Ingelheim
QuintilesIMS
Cipla

Generated: April 20, 2018

DrugPatentWatch Database Preview

Mylan Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for MYLAN PHARMS INC, and when can generic versions of MYLAN PHARMS INC drugs launch?

MYLAN PHARMS INC has two hundred and forty-two approved drugs.

There are eleven US patents protecting MYLAN PHARMS INC drugs. There are twenty-nine tentative approvals on MYLAN PHARMS INC drugs.

There are one hundred and ninety-one patent family members on MYLAN PHARMS INC drugs in thirty-nine countries and four hundred and thirteen supplementary protection certificates in thirteen countries.

Summary for Mylan Pharms Inc
International Patents:191
US Patents:11
Tradenames:198
Ingredients:188
NDAs:242

Drugs and US Patents for Mylan Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc AVITA tretinoin CREAM;TOPICAL 020404-003 Jan 14, 1997 AB RX No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc FLUVASTATIN SODIUM fluvastatin sodium TABLET, EXTENDED RELEASE;ORAL 202458-001 Sep 11, 2015 AB RX No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc DIDANOSINE didanosine CAPSULE, DELAYED REL PELLETS;ORAL 090788-001 Apr 8, 2010 DISCN No No ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc ERYGEL erythromycin GEL;TOPICAL 050617-001 Oct 21, 1987 AT RX Yes Yes ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Mylan Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Pharms Inc OLUX clobetasol propionate AEROSOL, FOAM;TOPICAL 021142-001 May 26, 2000 6,126,920 ➤ Sign Up
Mylan Pharms Inc ZOVIRAX acyclovir CAPSULE;ORAL 018828-001 Jan 25, 1985 4,199,574 ➤ Sign Up
Mylan Pharms Inc AVITA tretinoin CREAM;TOPICAL 020404-003 Jan 14, 1997 4,971,800 ➤ Sign Up
Mylan Pharms Inc ZONALON doxepin hydrochloride CREAM;TOPICAL 020126-001 Apr 1, 1994 4,395,420 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MYLAN PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Foam 0.12% ➤ Subscribe 2007-08-10
➤ Subscribe Foam 2% ➤ Subscribe 2009-07-30
➤ Subscribe Topical Foam 0.05% ➤ Subscribe 2005-06-27

Non-Orange Book US Patents for Mylan Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,250,688 Purine derivatives ➤ Sign Up
5,684,153 Process for the preparation of purine derivatives ➤ Sign Up
5,886,215 2-acetoxymethyl-4-halo-butyl-1-yl acetates ➤ Sign Up
5,075,445 Guanine derivatives ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Mylan Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
330 Luxembourg ➤ Sign Up CERTIFICATE TITLE: UNE COMBINAISON D'OLMESARTAN MEDOXOMIL, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET D'HYDROCHLOROTHIAZIDE (OLMETEC PLUS)
00086 Netherlands ➤ Sign Up PRODUCT NAME: IMATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESILAAT; NATL. REGISTRATION NO/DATE: EU/1/01/198/001 - 006 20011107; FIRST REGISTRATION: CH IKS 55807 20010621
C/GB05/042 United Kingdom ➤ Sign Up PRODUCT NAME: MESYLATE, ESYLATE OR SULFATE SALTS OF N-PROPARGYL-1(R)-AMINOINDAN (RASAGILINE); REGISTERED: UK EU/1/04/304/001 20050221; UK EU/1/04/304/002 20050221; UK EU/1/04/304/003 20050221; UK EU/1/04/304/004 20050221; UK EU/1/04/304/005 20050221; UK EU/1/04/304/006 20050221; UK EU/1/04/304/007 20050221
00357 Netherlands ➤ Sign Up PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Chubb
Boehringer Ingelheim
Daiichi Sankyo
Farmers Insurance
Fish and Richardson
Express Scripts
Queensland Health
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.